Neuraxpharm enters booming CBD market with the acquisition of leading Switzerland-based S.T.U GMBH

-Neuraxpharm establishes Swiss footprint with acquisition of leading cannabidiol company

-S.T.U. GmbH is the owner of market leading brand Hemplix™

October 29, 2019

Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), announces today the acquisition of S.T.U. GmbH (Swiss Trade Union or S.T.U.), a leading Switzerland-based developer and distributor of natural cannabidiol (CBD) consumer products.

The deal enables Neuraxpharm to enter the fast-growing CBD space and to build on its business of CNS-related products, including value added medicines, standard generics and consumer healthcare products. The acquisition is in line with Neuraxpharm’s strategy to expand its presence in Europe entering a key market. Switzerland is now the 10th European market where Neuraxpharm will have a direct presence. It is the fifth country the company has extended its footprint in 2019.

Read more 

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...